G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not

Retrovirology

Volumn 8, Issue , 2011, Pages

  Ni, Xiao Ju ^a,b   Delelis, Olivier ^a   Charpentier, Charlotte ^c   Storto, Alexandre ^c   Collin, Gilles ^c   Damond, Florence ^c   Descamps, Diane ^c   Mouscadet, Jean François ^a  

^a Ecole Normale Superieure de Cachan   (France)

^b EAST CHINA NORMAL UNIVERSITY   (China)

^c BICHAT HOSPITAL   (France)

Author keywords

HIV 2; Integrase; Mutation; Raltegravir; Resistance

Indexed keywords

INTEGRASE; RALTEGRAVIR; RECOMBINANT ENZYME; 2 PYRROLIDONE DERIVATIVE; INTEGRASE INHIBITOR;

ARTICLE; BLOOD SAMPLING; CATALYSIS; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; ENZYME ISOLATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IN VITRO STUDY; MOLECULAR CLONING; MUTAGENESIS; NONHUMAN; VIRUS GENOME; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MISSENSE MUTATION; MOLECULAR GENETICS; PROTEIN MOTIF; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-2; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PYRROLIDINONES;

EID: 80051782593     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-8-68     Document Type: Article

References (36)

1. Matheron S, Mendoza-Sassi G, Simon F, Olivares R, Coulaud JP, Brun-Vezinet F. HIV-1 and HIV-2 AIDS in African patients living in Paris. Aids 1997, 11:934-936.
2. Reeves JD, Doms RW. Human immunodeficiency virus type 2. J Gen Virol 2002, 83:1253-1265.
3. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004, 9:57-65.
4. Poveda E, Rodes B, Toro C, Soriano V. Are fusion inhibitors active against all HIV variants?. AIDS Res Hum Retroviruses 2004, 20:347-348. 10.1089/088922204322996590, 15117459.
5. Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S, Mammano F, Lastere S, Farfara I, Simon F, Chene G, Descamps D. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol 2005, 43:484-487. 10.1128/JCM.43.1.484-487.2005, 540186, 15635022.
6. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Benard A, Campa P, Matheron S, Chene G, Brun-Vezinet F, Descamps D. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008, 52:1545-1548. 10.1128/AAC.01284-07, 2292533,2292533, 18227188.
7. Rodes B, Sheldon J, Toro C, Jimenez V, Alvarez MA, Soriano V. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 2006, 57:709-713. 10.1093/jac/dkl034, 16464891.
8. Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother 2007, 51:604-610. 10.1128/AAC.00870-06, 1797771, 17116674.
9. Pieniazek D, Rayfield M, Hu DJ, Nkengasong JN, Soriano V, Heneine W, Zeh C, Agwale SM, Wambebe C, Odama L, Wiktor SZ. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. Aids 2004, 18:495-502. 10.1097/00002030-200402200-00016, 15090802.
10. Bercoff DP, Triqueneaux P, Lambert C, Oumar AA, Ternes AM, Dao S, Goubau P, Schmit JC, Ruelle J. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology 2010, 7:98. 10.1186/1742-4690-7-98, 3006360, 21114823.
11. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, Campa P, Chene G, Brun-Vezinet F, Descamps D. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008, 62:914-920. 10.1093/jac/dkn335, 18718922.
12. Zolopa AR. The evolution of HIC treatment guidelines: Current state-of-te-art of ART. Antiviral Res 2010, 85:241-244. 10.1016/j.antiviral.2009.10.018, 19883695.
13. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369:1261-1269. 10.1016/S0140-6736(07)60597-2, 17434401.
14. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007, 46:125-133. 10.1097/QAI.0b013e318157131c, 17721395.
15. Xu L, Anderson J, Garrett N, Ferns B, Wildfire A, Cook P, Workman J, Graham S, Smit E. Dynamics of raltegravir resistance profile in an HIV type 2-infected patient. AIDS Res Hum Retroviruses 2009, 25:843-847. 10.1089/aid.2009.0039, 19618998.
16. Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, Subra F, Deprez E, Mouscadet JF. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 2009, 37:1193-1201. 2651800, 19129221.
17. Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, Sayon S, Calvez V, Deprez E, Marcelin AG, Tchertanov L, Mouscadet JF. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother 2010, 54:491-501. 10.1128/AAC.01075-09, 2798554, 19901095.
18. Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V, Marcelin AG. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008, 52:1351-1358. 10.1128/AAC.01228-07, 2292515, 18227187.
19. Sichtig N, Sierra S, Kaiser R, Daumer M, Reuter S, Schulter E, Altmann A, Fatkenheuer G, Dittmer U, Pfister H, Esser S. Evolution of raltegravir resistance during therapy. J Antimicrob Chemother 2009, 64:25-32. 10.1093/jac/dkp153, 19447792.
20. Reigadas S, Anies G, Masquelier B, Calmels C, Stuyver LJ, Parissi V, Fleury H, Andreola ML. The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions. PLoS One 2010, 5:e10311. 10.1371/journal.pone.0010311, 2859942, 20436677.
21. Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chene G, Storto A, Collin G, Benard A, Damond F, Mouscadet JF, Brun-Vezinet F, Descamps D. Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir. Antimicrob Agents Chemother 2011, 55:1293-1295. 10.1128/AAC.00942-10, 21189351.
22. Salgado M, Toro C, Simon A, Garrido C, Blanco F, Soriano V, Rodes B. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J Clin Virol 2009, 46:173-175. 10.1016/j.jcv.2009.06.020, 19625211.
23. Metifiot M, Maddali K, Naumova A, Zhang X, Marchand C, Pommier Y. Biochemical and Pharmacological Analyses of HIV-1 Integrase Flexible Loop Mutants Resistant To Raltegravir. Biochemistry 2010, 49:3715-3722. 10.1021/bi100130f, 2866738, 20334344.
24. Leh H, Brodin P, Bischerour J, Deprez E, Tauc P, Brochon JC, LeCam E, Coulaud D, Auclair C, Mouscadet JF. Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase. Biochemistry 2000, 39:9285-9294. 10.1021/bi000398b, 10924121.
25. Bhattacharjya S, Balaram P. Effects of organic solvents on protein structures: observation of a structured helical core in hen egg-white lysozyme in aqueous dimethylsulfoxide. Proteins 1997, 29:492-507. 10.1002/(SICI)1097-0134(199712)29:4<492::AID-PROT9>3.0.CO;2-A, 9408946.
26. Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, Anderson J. Raltegravir treatment response in an HIV-2 infected patient: a case report. Aids 2008, 22:1091-1092. 10.1097/QAD.0b013e3282f9b165, 18520356.
27. Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, Toledano D, Descamps D, Brun-Vezinet F, Matheron S. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. Aids 2008, 22:665-666. 10.1097/QAD.0b013e3282f51203, 18317013.
28. Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L. Resistance to HIV-1 integrase inhibitors: A structural perspective. Drug Resist Updat 2010, 13:139-150. 10.1016/j.drup.2010.05.001, 20570551.
29. Roquebert B, Blum L, Collin G, Damond F, Peytavin G, Leleu J, Matheron S, Chene G, Brun-Vezinet F, Descamps D. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. Aids 2008, 22:2045-2046. 10.1097/QAD.0b013e32830f4c7d, 18784469.
30. Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Belec L, Weiss L, Si-Mohamed A, Piketty C. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008, 9:765-770. 10.1111/j.1468-1293.2008.00628.x, 18651855.
31. Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci USA 2010, 107:20057-20062. 10.1073/pnas.1010246107, 2993412, 21030679.
32. Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet JF, Campa P, Chêne G, Brun-Vezinet F, Descamps D. Long-Lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir removal. Antiviral Therapy 2011,
33. Reigadas S, Masquelier B, Calmels C, Laguerre M, Lazaro E, Vandenhende M, Neau D, Fleury H, Andréola ML. Structure analysis of HIV-1 IN Y143C/R Raltegravir resistance mutation in association with the secondary mutation T97A. Antimicrob Agents Chemother 2011, 55:3187-3194. 10.1128/AAC.00071-11, 21576445.
34. Métifiot M, Vandegraaft N, Maddali K, Naumova A, Zhang X, Rhodes D, Marchand C, Pommier Y. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation 143. Aids 2011, 25:1175-1178. 10.1097/QAD.0b013e3283473599, 21505303.
35. Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009, 11:17-29.
36. Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, Scopelliti F, Pollicita M, Van Wesenbeeck L, Van Eygen V, Dori L, Sarmati L, Aquaro S, Palamara G, Andreoni M, Stuyver LJ, Perno CF. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother 2010, 54:3938-3948. 10.1128/AAC.01720-09, 2935022, 20479206.